Pfizer, a pacesetter among global biopharmaceutical companies, has been established in China since the 1980s. Pfizer’s presence and activities in China started with commercial offices, and has evolved to incorporate manufacturing (e.g., several plants commenced operations in China during the 1980s and 1990s, including Dalian and Suzhou), also as R&D – with the establishment of Pfizer’s China R&D Center (CRDC) in Shanghai in 2005. The last decade has seen a big expansion of Pfizer’s R&D footprint, facilities and capabilities, notably with the launch of CRDC’s sister satellite R&D site in Wuhan in 2010. Currently the market leader among multinational biopharmaceutical companies in China, Pfizer has approximately 1,500 R&D colleagues working in China, with a degree in three key sites affiliated to CRDC – namely Shanghai, Wuhan and Beijing.
CRDC supports Pfizer’s global biological and chemical pharmaceutical R&D programs across our clinical development pipeline, and is a crucial hub of Pfizer global and Asia-Pacific R&D activities. As such, CRDC is an integral a part of Pfizer’s global R&D site network, providing support across many R&D disciplines, including clinical drug development, medical, regulatory and safety.
CRDC has continually contributed to the biopharmaceutical R&D environment in China to market the R&D of innovative medicines in China. we’ve partnered on many collaborative efforts with leading academic institutions and universities, including Peking University, Tsinghua University, Fudan University, and therefore the China Academy of Sciences. CRDC has sponsored, chaired and presented at many external workshops, industry and academic conferences in China, including multiple workshops for the middle of Drug Evaluation (CDE) and Center of Drug Re-Evaluation (CDR) of the CFDA, on clinical pharmacology and pharmacometrics, pharmacovigilance and safety reporting, data processing , clinical data management, among other areas.
CRDC’s aspiration is to assist accelerate China’s transition to an innovative economy by catalyzing the upgrade of local R&D capabilities, systems, technologies/IP, and culture, to deal with unmet medical needs, and make a world-class biopharmaceutical R&D ecosystem for China, as a part of the worldwide R&D community. We certainly will still innovate and convey important new medicines from Pfizer’s pipeline to patients in China.
Pfizer is expanding its R&D efforts in China and announced plans to create a replacement facility.
An agreement has been signed to determine a replacement Pfizer R&D centre in Wuhan, which the firm says represents an expansion of its existing facility in Shanghai. Once the new plant is made , the corporate expects the amount of employees to grow to 200 within three years but gave no details about the financial investment involved.
Pfizer noted that its Wuhan operation will liaise with local research institutes and universities “utilising the rich resources of local talent and existing industry capabilities to develop research collaborations”. It stressed that Shanghai will remain “the operations hub of Pfizer’s R&D effort in China”.
Allan Gabor, the company’s North Asia president, noted that it’s the primary to determine a big R&D presence in China’s Central/Western region. He added that the Wuhan centre are going to be an integral a part of Pfizer’s global R&D operations “while being closely aligned with the Chinese government’s strategy on biopharmaceutical industry development within the region.”
The site are going to be based at the Wuhan National Bioindustry Base, or Biolake, the development that started in November last year.